APA

Michelson D., Snyder E., Paradis E., Chengan-Liu M., Snavely D. B., Hutzelmann J., Walsh J. K., Krystal A. D., Benca R. M., Cohn M., Lines C., Roth T. & Herring W. J. (20140602). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. : The Lancet. Neurology.

Chicago

Michelson David, Snyder Ellen, Paradis Erin, Chengan-Liu Mary, Snavely Duane B, Hutzelmann Jill, Walsh James K, Krystal Andrew D, Benca Ruth M, Cohn Martin, Lines Christopher, Roth Thomas and Herring W Joseph. 20140602. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. : The Lancet. Neurology.

Harvard

Michelson D., Snyder E., Paradis E., Chengan-Liu M., Snavely D. B., Hutzelmann J., Walsh J. K., Krystal A. D., Benca R. M., Cohn M., Lines C., Roth T. and Herring W. J. (20140602). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. : The Lancet. Neurology.

MLA

Michelson David, Snyder Ellen, Paradis Erin, Chengan-Liu Mary, Snavely Duane B, Hutzelmann Jill, Walsh James K, Krystal Andrew D, Benca Ruth M, Cohn Martin, Lines Christopher, Roth Thomas and Herring W Joseph. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. : The Lancet. Neurology. 20140602.